Consistent with these observations, breast cancer patients with overexpressed RAD51 (n = 270) displayed decreased survival probability (p = 0.0045) compared to the patients with low/medium-level RAD51 expression (n = 811) (Fig. 7c). This evidence concerns the gene RAD51 and breast carcinoma.